Medicus Pharma Ltd. MDCX
Our company (formerly, Interactive Capital Partners Corporation) was incorporated pursuant to the Business Corporations Act (Ontario) on April 30, 2008 under the name Interactive Capital Partners Corporation.
On September 29, 2023, the Company completed a business combination (the "Business Combination") with SkinJect Inc. ("SkinJect"), a company existing under the laws of Pennsylvania. The Business Combination was completed pursuant to a business combination agreement dated May 12, 2023, as amended, among the Company, SkinJect and RBx Capital, LP ("RBx"), an investment entity owned and managed by Dr. Raza Bokhari, and resulted in a reverse takeover of the Company by the former shareholders of SkinJect, with SkinJect becoming a wholly owned operating subsidiary of the Company, and the Company being renamed "Medicus Pharma Ltd."
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D | $7.7M | $3.5M | $193.6K | — |
| SG&A | $17.9M | $7.7M | $4.5M | — |
| Total operating expenses | $34.4M | $11.2M | $4.7M | — |
| Operating income | -$34.4M | -$11.2M | -$4.7M | — |
| Interest expense | $197.4K | $25.4K | — | — |
| Pre-tax income | -$47.3M | -$11.2M | -$5.3M | — |
| Income tax | $0 | $0 | $0 | — |
| Net income | -$47.3M | -$11.2M | -$5.3M | — |
| EPS, basic | -2.74 | -1.16 | -1.53 | — |
| EPS, diluted | -2.74 | -1.16 | -1.53 | — |
| Shares, diluted (wtd. avg.) | $17.3M | $9.6M | $3.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $8.7M | $4.2M | $1.7M | $267.7K |
| Total current assets | $9.9M | $5.4M | $1.9M | — |
| Total assets | $10.1M | $5.6M | $1.9M | — |
| Accounts payable | $3.4M | $1.3M | $210.8K | — |
| Short-term debt | $5.2M | $0 | — | — |
| Total current liabilities | $9.9M | $2.3M | $781.6K | — |
| Total liabilities | $10.0M | $2.5M | $781.6K | — |
| Retained earnings | -$64.3M | -$28.9M | -$17.7M | — |
| Total equity | -$67.6K | $3.1M | $1.1M | -$12.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$22.8M | -$10.2M | -$4.2M | — |
| Stock-based compensation | $1.5M | $713.1K | $98.6K | — |
| Investing cash flow | -$4.6M | $0 | — | — |
| Financing cash flow | $31.9M | $12.7M | $5.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001062993-26-002212.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |